Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:17:48 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ORXOY - OREXO AB SPON ADR EA REPR 1 ORD SEK0.0 - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ORXOY - Qnot subscribed1.40    1.60  0.76Apr 24Apr 0215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-02 07:23U:ORXOYNews ReleaseOrexo announces that the condition for early redemption of its existing bonds has been fulfilled
2024-03-28 03:13U:ORXOYNews ReleaseOrexo publishes the Annual and Sustainability Report for 2023
2024-03-22 04:39U:ORXOYNews ReleaseCorrection: Notice of Annual General Meeting of Orexo
2024-03-15 05:20U:ORXOYNews ReleaseNotice of Annual General Meeting of Orexo
2024-03-13 16:08U:ORXOYNews ReleaseOrexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
2024-03-08 02:24U:ORXOYNews ReleaseOrexo strengthens its sustainability work by establishing a social financing framework
2024-03-08 02:23U:ORXOYNews ReleaseOrexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
2024-02-12 02:09U:ORXOYNews ReleaseOrexo and Sobi agree to advance feasibility study with AmorphOX
2024-02-08 02:23U:ORXOYNews ReleaseOrexo Interim Report Q4 2023, incl. Full Year Report
2024-02-06 02:09U:ORXOYNews ReleaseOrexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC
2023-11-28 02:29U:ORXOYNews ReleaseOrexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose
2023-11-02 03:20U:ORXOYNews ReleaseOrexo Q3 2023 Interim Report
2023-10-27 02:40U:ORXOYNews ReleaseOrexo announces changes in the company ‚ ´s Board of Directors
2023-10-26 11:10U:ORXOYNews ReleaseOrexo ‚ ´s Nomination Committee for the Annual General Meeting 2024
2023-10-26 10:18U:ORXOYNews ReleaseReport from Orexo ‚ ´s extraordinary general meeting
2023-10-11 03:01U:ORXOYNews ReleaseOrexo announces data from the MODIA ‚ ® study evaluating impact on use of illicit opioids
2023-10-03 04:29U:ORXOYNews ReleaseNotice of Extraordinary General Meeting in Orexo AB (publ)
2023-09-18 02:37U:ORXOYNews ReleaseOrexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
2023-09-05 08:08U:ORXOYNews ReleaseOrexo to participate in Pareto Securities ‚ ´ 14th Annual Healthcare Conference 2023
2023-08-29 02:16U:ORXOYNews ReleaseOrexo secures patent protection in the US for OX640, a nasal epinephrine powder product